ATLANTA, November 12, 2020
Micron Biomedical, Inc. (Micron) was awarded a new research contract by the Centers for Disease Control and Prevention (CDC) to manufacture IRV microneedle patches for future clinical evaluation. Micron and CDC have been collaborating on the development of the IRV microneedle patch for several years. Preclinical studies of the IRV vaccine, developed by the CDC, delivered using Micron’s dissolving microneedle patch technology show that the IRV microneedle patch is immunogenic and safe in animals. Under this new contract, Micron will leverage the work done under previous funding to manufacture IRV microneedle patches under cGMP conditions.